- Home
- QNRX
as 06-06-2025 4:00pm EST
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | KFAR SABA |
| Market Cap: | 3.3M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 522.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -39.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.01 - $54.95 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Quoin Pharmaceuticals Ltd. News
QNRX Breaking Stock News: Dive into QNRX Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
10 days ago
QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further
MT Newswires
16 days ago
Quoin Pharmaceuticals Says US FDA Clears Second Netherton Syndrome Pivotal Study
GlobeNewswire
16 days ago
Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study
GlobeNewswire
18 days ago
Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome
MT Newswires
24 days ago
Quoin Says Early Preliminary Results From Pediatric Skin Disorder Trial Therapy Shows 'Clear Evidence' of Healing
GlobeNewswire
24 days ago
Quoin Pharmaceuticals Announces Initial Positive Clinical Data for QRX003 from Pediatric Peeling Skin Syndrome Study
GlobeNewswire
25 days ago
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2025 Financial Results
GlobeNewswire
a month ago
Quoin Pharmaceuticals to Announce First Quarter 2025 Financial Results on Tuesday, May 13, 2025
Compare QNRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "QNRX Quoin Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.